Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Xiaowei Fu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1254-0632; OpenAlex author ID A5101975313, A5129808725. Sources: OpenAlex.

Their work

Papers
8 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 8

  1. Vaccinia-related kinase 2 inhibition elicits vulnerability of glutathione metabolism in pancreatic cancer. First author DOI 10.1038/s41419-026-08573-9↗
  2. ESCO1 stabilizes NUFIP2 through acetylation-ubiquitination crosstalk to promote pancreatic cancer progression. Co-author DOI 10.3389/fimmu.2026.1929713↗
  3. Hsa_circ_0046523 Mediates an Immunosuppressive Tumor Microenvironment by Regulating MiR-148a-3p/PD-L1 Axis in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.877376↗
  4. EPS8 supports pancreatic cancer growth by inhibiting BMI1 mediated proteasomal degradation of ALDH7A1. Co-author DOI 10.1016/j.yexcr.2021.112782↗
  5. E3 ubiquitin ligase TRIM29 promotes pancreatic cancer growth and progression via stabilizing Yes-associated protein 1. First author DOI 10.1186/s12967-021-03007-w↗
  6. MicroRNA-148a-3p suppresses epithelial-to-mesenchymal transition and stemness properties via Wnt1-mediated Wnt/β-catenin pathway in pancreatic cancer. Co-author DOI 10.1111/jcmm.15900↗
  7. Downregulation of NEAT1 sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine through modulation of the miR-506-3p/ZEB2/EMT axis Co-author DOI 10.21203/rs.3.rs-86053/v1↗
  8. CHD1L Expression Increases Tumor Progression and Acts as a Predictive Biomarker for Poor Prognosis in Pancreatic Cancer. First author DOI 10.1007/s10620-017-4641-8↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Weidong Xiao · 3 shared papers, 2020–2022 · strength 0.40
  2. Yeqing Zou · 3 shared papers, 2017–2021 · strength 0.34
  3. Letian Chen · 1 shared paper, 2026 · strength 0.32
  4. Yeqing Zou · 1 shared paper, 2026 · strength 0.32
  5. Long Liu · 1 shared paper, 2026 · strength 0.30
  6. Zhiyu Li · 1 shared paper, 2026 · strength 0.30
  7. Sisi Chen · 1 shared paper, 2026 · strength 0.30
  8. Xueqiang Deng · 2 shared papers, 2020–2021 · strength 0.27
  9. Gen Sun · 2 shared papers, 2020–2022 · strength 0.27
  10. Bo Huang · 2 shared papers, 2017–2020 · strength 0.20
  11. Mingzhu Tan · 1 shared paper, 2021 · strength 0.17
  12. Ruihao Wang · 1 shared paper, 2021 · strength 0.17
  13. Lu Fang · 1 shared paper, 2021 · strength 0.14
  14. Wanpeng Xin · 1 shared paper, 2020 · strength 0.11
  15. Le Hong · 1 shared paper, 2020 · strength 0.11
  16. Chuan Liu · 1 shared paper, 2017 · strength 0.07
  17. Zhiwei Zhong · 1 shared paper, 2017 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.